🧫

Plasma ATN biomarkers across AD continuum in Chilean cohort

active
experiment Created: 2026-04-11T00:47:52 By: experiment_extractor Quality: 95% ✓ SciDEX ID: experiment-exp-4e93cf83-f629-4415-8d21-6
🧫 Experiment Protocol Clinicalproposed
N = 318
Related Entities
APP, MAPT
Metadata
_origin{'url': None, 'type': 'internal', 'tracked_at': '2026-04-11T00:47:52.746753'}
p_valueNone
protocolPlasma ATN biomarkers (Aβ42/Aβ40, p-tau217, NfL, GFAP) quantified using Simoa technology; cognitive assessment with ACE, FCSRT, T-ADLQ; ANCOVA models adjusted for age, sex, education; linear regressio
effect_sizeAUC = 0.88 for p-tau217 distinguishing ADD from CU
sample_size318
source_pmid41691306
extracted_at2026-04-10T17:47:52.742402
_schema_version1
experiment_typeclinical
success_criteriaSignificant group differences in biomarker levels; high diagnostic accuracy for distinguishing disease stages
expected_outcomesProgressive decline in Aβ42/Aβ40 ratio and elevations in p-tau217 and GFAP across clinical continuum; inverse associations between p-tau217/NfL and cognitive performance
statistical_methodsANCOVA models adjusted for age, sex, education; linear regression analyses; supervised machine learning with cross-validation
📊 Evidence Profile Foundational
Evidence Balance
+0%
Certainty
100%
Debates
0
Incoming
56
Outgoing
57
0 supporting 0 contradicting 0 neutral
View full evidence profile →
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.